Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth
Oral presentation will feature new data for investigational REGN7075, an EGFRxCD28 costimulatory bispecific with the potential to enhance the treatment of certain advanced solid tumors in combination...
Oral presentations include updated results from clinical study of otoferlin gene therapy DB-OTO demonstrating restoration in children with profound genetic hearing loss Additional presentations...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
US FDA warns of harmful reactions to fake Botox injections
New York-based pharma Regeneron announced Monday that it is launching a $500 million venture capital fund that will invest in promising biotechnology innovation amid a renewed wave of investment activity in the biotech market.
BOSTON, April 10 (Reuters) - The U.S. Justice Department on Wednesday accused Regeneron Pharmaceuticals (REGN.O), opens new tab of manipulating Medicare's drug-pricing process by inflating the average sales price for its expensive macular degeneration drug Eylea.
TARRYTOWN, N.Y., April 07, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the oral plenary session presentation of positive pivotal data from the Phase 1/2...
2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron